Trials / Completed
CompletedNCT04822103
A Real-World Study of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer
A Real-World Study Evaluating the Effectiveness and Safety of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 155 (actual)
- Sponsor
- Guangdong Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The role of preoperative chemotherapy as standard therapy is well-established for advanced esophageal cancer. Immunotherapeutic agents such as Immune checkpoint inhibitors has been shown to improve objective response rate in solid tumors. However, there is a paucity of data regarding the efficacy and safety of preoperative immunotherapy plus chemotherapy in esophageal cancer patients in real-world practice. This study set out to investigate whether the combination of preoperative chemotherapy and immune checkpoint inhibitors is beneficial to improve the objective response rate as well as the pathological complete response rate in a real-world scenario.
Conditions
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2021-10-01
- Completion
- 2021-10-31
- First posted
- 2021-03-30
- Last updated
- 2022-03-18
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04822103. Inclusion in this directory is not an endorsement.